Reproductive Endocrinology Practice Questions

Q: Which of the following drugs cannot be used in the treatment of hirsutism in Polycystic Ovarian Disease (PCOD)?

Menopausal gonadotropin. **Explanation:** The goal of treating hirsutism in PCOD is to lower circulating androgen levels or block their action at the hair follicle. **Why Menopausal Gonadotropin is the correct answer:** Human Menopausal Gonadotropin (hMG) contains **Follicle Stimulating Hormone (FSH) and Luteal Hormone (LH)**. In PCOD, there is already a characteristic high LH:FSH ratio. Administering exogenous gonadotropins stimulates the ovaries to produce more estrogen and androgens, potentially worsening the hormonal imbalance and hirsutism. hMG is used for **ovulation induction** in infertile patients, not for treating androgenic symptoms. **Analysis of incorrect options:** * **GnRH Agonists:** Long-acting GnRH analogues cause pituitary desensitization, leading to a "medical oophorectomy." This suppresses ovarian androgen production, making it an effective (though second-line) treatment for severe hirsutism. * **Spironolactone:** This is a potassium-sparing diuretic that acts as an **androgen receptor antagonist** and inhibits 5-alpha reductase. It is a mainstay in the medical management of hirsutism. * **Metformin:** As an insulin sensitizer, it reduces hyperinsulinemia. Lower insulin levels lead to a decrease in ovarian androgen production and an increase in Sex Hormone Binding Globulin (SHBG), which reduces free testosterone. **Clinical Pearls for NEET-PG:** * **First-line treatment** for hirsutism in PCOD is usually Combined Oral Contraceptive Pills (COCPs). * **Spironolactone** must be used with contraception due to the risk of feminization of a male fetus. * **Finasteride** (5-alpha reductase inhibitor) and **Flutamide** (pure anti-androgen) are other options. * It takes **6–9 months** of therapy to see clinical improvement in hirsutism due to the long hair growth cycle.

Q: A patient with amenorrhea presents with bleeding after a progesterone challenge test. What does this finding imply?

All of the above.. The **Progesterone Challenge Test (PCT)** is a fundamental diagnostic tool used to assess the functional integrity of the reproductive tract in patients with amenorrhea. ### **Why Option D is Correct** A positive result (withdrawal bleeding within 2–7 days of stopping progesterone) confirms several physiological prerequisites: 1. **Sufficient Endogenous Estrogen (Option A):** Progesterone can only cause withdrawal bleeding if the endometrium has been previously "primed" by estrogen. Estrogen causes endometrial proliferation; without it, progesterone cannot induce the secretory changes necessary for shedding. 2. **Intact Pituitary-Ovarian Axis (Option B):** The presence of estrogen implies that the ovaries are functioning and are being stimulated by gonadotropins (FSH/LH) from the pituitary gland. 3. **Normal Ovarian Function & Intact Endometrium (Option C):** Bleeding confirms that the outflow tract (uterus, cervix, and vagina) is patent and the endometrium is responsive to hormonal fluctuations. ### **Clinical Pearls for NEET-PG** * **The "Positive" PCT:** If bleeding occurs, the diagnosis is usually **Anovulation** (e.g., PCOS). The patient has estrogen but lacks progesterone because they aren't ovulating. * **The "Negative" PCT:** If no bleeding occurs, it indicates either **Estrogen deficiency** (Hypogonadotropic hypogonadism or Premature Ovarian Failure) or an **Outflow tract obstruction** (Asherman’s syndrome or Mullerian anomalies). * **Next Step after Negative PCT:** Perform an **Estrogen-Progesterone Challenge Test**. If bleeding occurs now, the outflow tract is patent, and the problem is a lack of estrogen. If bleeding still does not occur, the diagnosis is an outflow tract obstruction. * **Dosage:** Commonly Medroxyprogesterone acetate (10 mg) for 5–10 days.

Q: Polycystic ovarian syndrome is characterized by all EXCEPT:

Normal FSH/LH ratio. **Explanation:** Polycystic Ovarian Syndrome (PCOS) is a complex endocrine disorder characterized by a disruption in the hypothalamic-pituitary-ovarian axis. **Why Option D is the Correct Answer:** In PCOS, there is an increased frequency of GnRH pulses, which preferentially stimulates the anterior pituitary to secrete **Luteinizing Hormone (LH)** over **Follicle Stimulating Hormone (FSH)**. This leads to a **reversal or elevation of the FSH/LH ratio**, typically reaching **1:2 or 1:3**. Therefore, a "normal" ratio (usually 1:1) is not characteristic of the syndrome. **Analysis of Incorrect Options:** * **A. Hyperandrogenemia:** This is a hallmark of PCOS. High LH levels stimulate the ovarian theca cells to produce excess androgens (androstenedione and testosterone), leading to hirsutism and acne. * **B. Normal or raised estrogen:** While patients are often anovulatory (lacking progesterone), they maintain constant levels of estrogen. This is due to the peripheral conversion of androgens into **Estrone (E1)** in adipose tissue, leading to a state of "unopposed estrogen." * **C. Raised LH:** As mentioned, increased GnRH pulse frequency leads to persistently elevated LH levels, which is a classic biochemical finding in these patients. **High-Yield Clinical Pearls for NEET-PG:** * **Rotterdam Criteria (2 out of 3):** 1. Oligo/Anovulation, 2. Clinical/Biochemical Hyperandrogenism, 3. Polycystic ovaries on USG (≥12 follicles or volume >10ml). * **Gold Standard Investigation:** Serum Free Testosterone (most sensitive). * **Insulin Resistance:** A key feature; hyperinsulinemia decreases SHBG, further increasing free androgen levels. * **String of Pearls:** Classic USG appearance of follicles (2-9mm) arranged peripherally.

Q: Which of the following pharmacological agents is NOT used in the management of polycystic ovarian syndrome (PCOS)?

Danazol. **Explanation:** The management of Polycystic Ovarian Syndrome (PCOS) is tailored to the patient’s primary complaint: menstrual irregularity, hyperandrogenism, or infertility. **Why Danazol is the correct answer:** Danazol is a synthetic steroid with **strong androgenic properties**. It is primarily used to suppress the pituitary-ovarian axis in conditions like endometriosis and fibrocystic breast disease. Since PCOS is already characterized by **hyperandrogenism** (elevated testosterone and androstenedione), administering Danazol would worsen clinical symptoms like hirsutism and acne. Therefore, it is contraindicated in PCOS. **Why the other options are used:** * **Oral Contraceptive Pills (OCPs):** These are the **first-line treatment** for menstrual irregularity and hirsutism in women not seeking pregnancy. They regularize cycles, protect the endometrium from hyperplasia, and increase Sex Hormone Binding Globulin (SHBG), which lowers free testosterone. * **Cyclical Progesterones:** Used in patients who cannot take OCPs. They ensure regular withdrawal bleeding, preventing endometrial hyperplasia due to "unopposed estrogen." * **Letrozole:** An aromatase inhibitor that is currently the **drug of choice (DOC) for ovulation induction** in PCOS patients struggling with infertility. **NEET-PG High-Yield Pearls:** * **DOC for Ovulation Induction in PCOS:** Letrozole (superior to Clomiphene citrate). * **DOC for Hirsutism in PCOS:** Combined OCPs (specifically those containing Cyproterone acetate or Drospirenone). * **Rotterdam Criteria:** Diagnosis requires 2 out of 3: (1) Oligo/Anovulation, (2) Clinical/Biochemical Hyperandrogenism, (3) Polycystic ovaries on USG. * **LH:FSH Ratio:** Classically elevated (3:1), though no longer a diagnostic criterion.

Q: What is the normal value of Anti-Mullerian Hormone?

2-6.8 ng/mL. **Explanation:** Anti-Mullerian Hormone (AMH) is a glycoprotein secreted by the **granulosa cells of pre-antral and small antral follicles** (less than 8mm). It serves as a reliable biochemical marker for **ovarian reserve**, reflecting the size of the primordial follicle pool. **Why Option B is Correct:** The normal physiological range for AMH in a healthy woman of reproductive age is typically **2–6.8 ng/mL**. Values in this range indicate an adequate ovarian reserve, suggesting a good potential response to controlled ovarian stimulation in ART (Assisted Reproductive Technology). **Analysis of Incorrect Options:** * **Option A ( 6.8 ng/ml):** Abnormally high levels of AMH (typically >5–7 ng/mL) are a classic diagnostic marker for **Polycystic Ovary Syndrome (PCOS)**, where there is an abundance of small antral follicles. Very high levels (>10 ng/ml) also increase the risk of Ovarian Hyperstimulation Syndrome (OHSS). **High-Yield Clinical Pearls for NEET-PG:** * **Cycle Independence:** Unlike FSH, LH, and Estradiol, AMH levels remain **stable throughout the menstrual cycle**; therefore, it can be tested on any day. * **Best Marker:** AMH is considered the best biochemical marker for ovarian reserve, while **Antral Follicle Count (AFC)** via ultrasound is the best biophysical marker. * **Clinical Use:** It is used to predict the timing of menopause and to individualize gonadotropin dosing in IVF. * **Oral Contraceptive Pills (OCPs):** AMH levels may be slightly suppressed in women taking long-term OCPs.

Q: A young woman presents with secondary amenorrhea and galactorrhea. MRI shows a pituitary tumor of less than 10mm diameter. What is the recommended treatment?

Bromocriptine. **Explanation:** The clinical presentation of secondary amenorrhea and galactorrhea, combined with an MRI showing a pituitary tumor <10 mm (Microadenoma), is diagnostic of a **Microprolactinoma**. **Why Bromocriptine is the Correct Answer:** In cases of prolactinomas, medical management is the first-line treatment regardless of the tumor size (micro or macro). **Dopamine agonists** like Bromocriptine or Cabergoline are the drugs of choice. They work by stimulating D2 receptors on lactotrophs, which inhibits prolactin secretion and leads to a reduction in tumor size. This restores the pulsatile secretion of GnRH, thereby correcting amenorrhea and stopping galactorrhea. **Why Other Options are Incorrect:** * **Hormonal therapy (Withdrawal bleeding):** This treats the symptom (amenorrhea) but not the underlying cause (hyperprolactinemia). It will not shrink the tumor or stop galactorrhea. * **Radiotherapy:** This is reserved for aggressive tumors or cases refractory to medical and surgical management due to the risk of panhypopituitarism. * **Chemotherapy:** Prolactinomas are benign tumors and do not respond to conventional cytotoxic chemotherapy. **High-Yield Clinical Pearls for NEET-PG:** * **Microadenoma:** <10 mm; **Macroadenoma:** ≥10 mm. * **Drug of Choice:** **Cabergoline** is currently preferred over Bromocriptine due to higher efficacy and fewer side effects (longer half-life), but Bromocriptine remains a standard answer in exams, especially for patients desiring pregnancy. * **Surgical Indication:** Transsphenoidal surgery is indicated only if the patient is resistant to/intolerant of dopamine agonists or if a macroadenoma causes visual field defects (bitemporal hemianopia). * **Hook Effect:** Extremely high prolactin levels can sometimes result in a falsely low lab reading; serial dilution is required for diagnosis.

Q: What are the typical serum Estrogen levels on Day 3 indicative of premature ovarian failure?

40 IU/L) is the diagnostic gold standard, serum Estrogen levels in POF are characteristically low. In a healthy, cycling female, Day 3 E2 levels are typically between 25–50 pg/ml. In POF, the follicles fail to develop, leading to hypoestrogenism. For NEET-PG purposes, a serum Estrogen level **<60–80 pg/ml** (specifically values consistently below the normal early follicular range) in the presence of high FSH confirms the failure of follicular steroidogenesis. **Analysis of Incorrect Options:** * **Options A and B (<10-40 pg/ml):** While these levels are indeed low, they represent "post-menopausal" or "pre-pubertal" ranges. In clinical practice and standardized exams, the threshold for defining the pathological decline in POF is generally set higher ( 4 months, and FSH >25-40 IU/L (on two occasions, 4 weeks apart). * **The "FSH-Estrogen" Paradox:** High FSH with *high* Day 3 Estrogen (>80-100 pg/ml) actually indicates **poor ovarian reserve**, as the high E2 prematurely suppresses FSH, potentially masking a high FSH reading. * **Best Marker for Ovarian Reserve:** Anti-Müllerian Hormone (AMH), as it is cycle-independent.

Q: What are the typical serum Anti-Müllerian hormone levels in Polycystic Ovary Syndrome (PCOS)?

Elevated. **Explanation:** **Correct Option: A. Elevated** In Polycystic Ovary Syndrome (PCOS), serum Anti-Müllerian hormone (AMH) levels are typically **2 to 4 times higher** than in healthy women. This elevation occurs due to two primary mechanisms: 1. **Increased Follicle Count:** AMH is produced by the granulosa cells of pre-antral and small antral follicles. The hallmark of PCOS is an excess of these small follicles (polycystic morphology), leading to a higher cumulative production of AMH. 2. **Increased Production per Follicle:** Research indicates that individual granulosa cells in PCOS patients produce more AMH than those in normal ovaries, likely due to an arrest in follicle development and altered feedback mechanisms. **Why other options are incorrect:** * **B. Decreased:** Low AMH is a marker of diminished ovarian reserve (e.g., Premature Ovarian Insufficiency or menopause), which is the physiological opposite of the follicular excess seen in PCOS. * **C & D. Unchanged/Variable:** While AMH levels can fluctuate slightly, the consistent clinical finding in PCOS is a significant elevation. It is rarely "normal" or "variable" in a way that would exclude its use as a diagnostic marker. **High-Yield Clinical Pearls for NEET-PG:** * **Diagnostic Utility:** Although not yet part of the formal Rotterdam Criteria, AMH is increasingly used as a surrogate marker for Polycystic Ovarian Morphology (PCOM) on ultrasound. * **Correlation:** AMH levels correlate directly with the severity of the disease and the degree of hyperandrogenism. * **Cycle Stability:** Unlike FSH/LH, AMH levels remain relatively stable throughout the menstrual cycle, making it a convenient "anytime" blood test. * **OHSS Risk:** High baseline AMH in PCOS patients is a significant predictor of Ovarian Hyperstimulation Syndrome (OHSS) during IVF.

Question 1

Which of the following drugs cannot be used in the treatment of hirsutism in Polycystic Ovarian Disease (PCOD)?

Accepted Answer

Menopausal gonadotropin

Answer

Gonadotropin-releasing hormone (GnRH)

Answer

Spironolactone

Answer

Metformin

Question 2

A patient with amenorrhea presents with bleeding after a progesterone challenge test. What does this finding imply?

Accepted Answer

All of the above.

Answer

Sufficient endogenous estrogen production.

Answer

An intact pituitary-ovarian axis.

Answer

Both normal ovarian function and an intact endometrium.

Question 3

Polycystic ovarian syndrome is characterized by all EXCEPT:

Accepted Answer

Normal FSH/LH ratio

Answer

Hyperandrogenemia

Answer

Normal or raised estrogen

Answer

Raised LH

Question 4

Which of the following pharmacological agents is NOT used in the management of polycystic ovarian syndrome (PCOS)?

Accepted Answer

Danazol

Answer

Oral contraceptive pills

Answer

Cyclical progesterones

Answer

Letrozole

Question 5

What is the normal value of Anti-Mullerian Hormone?

Accepted Answer

2-6.8 ng/mL

Answer

<1 ng/ml

Answer

6.8-10 ng/ml

Answer

>10 ng/ml

Question 6

A young woman presents with secondary amenorrhea and galactorrhea. MRI shows a pituitary tumor of less than 10mm diameter. What is the recommended treatment?

Accepted Answer

Bromocriptine

Answer

Hormonal therapy for withdrawal bleeding

Answer

Radiotherapy

Answer

Chemotherapy

Question 7

All are true regarding Polycystic Ovary Syndrome (PCOS) EXCEPT:

Accepted Answer

Metformin is the sole drug of choice

Answer

Increased sex hormone-binding globulin (SHBG) ratio

Answer

Increased LH/FSH ratio

Answer

Cause of infertility in women

Question 8

What are the typical serum Estrogen levels on Day 3 indicative of premature ovarian failure?

Accepted Answer

<60-80 pg/ml

Answer

<10-20 pg/ml

Answer

<20-40 pg/ml

Answer

<40-60 pg/ml

Question 9

A 24-year-old female presents with a chief complaint of hair growth all over her body. She reports that her menses began at age 13 and have always been very irregular. She also complains of acne. Physical examination reveals hair around the nipples, chin, and upper lip. There is no galactorrhea, thyromegaly, or temporal balding. Pelvic examination is normal, and there is no evidence of clitoromegaly. Which of the following should be included in the differential diagnosis based on the patient's history and physical examination?

Accepted Answer

Sertoli-Leydig cell tumor

Answer

Idiopathic hirsutism

Answer

Stein-Leventhal syndrome

Answer

Late-onset congenital adrenal hyperplasia

Question 10

What are the typical serum Anti-Müllerian hormone levels in Polycystic Ovary Syndrome (PCOS)?

Accepted Answer

Elevated

Answer

Decreased

Answer

Unchanged

Answer

Variable

Reproductive Endocrinology — MCQs

Reproductive Endocrinology — MCQs

On this page

Practice by Chapter

Want unlimited practice?